Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
People who inject drugs should have access to hepatitis C treatment, expert panel recommends

New recommendations on hepatitis C treatment and care for people who inject drugs encourage physicians to offer treatment to all people who inject drugs diagnosed with HCV,

Published
07 October 2015
By
Keith Alcorn
U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs

Three applications are under review for Daklinza in combination with sofosbuvir with or without ribavirin to treat chronic hepatitis C patients with decompensated cirrhosis, post-liver transplant recurrence of HCV, and coinfection with HIV-1.

Published
07 October 2015
From
Bristol-Myers Squibb
Rising death rates and burden of liver disease requires urgent hepatitis C treatment in people who inject or have injected drugs

Treating hepatitis C in people who inject drugs is the most cost effective way to address the sharp increase in liver disease and death resulting from hepatitis C infection, new research presented at a conference in Sydney today reveals.

Published
07 October 2015
From
Kirby Institute press release
NYU researchers find development of serious liver damage in mid- to late-adulthood among people who inject drugs with untreated chronic hepatitis C infection

Few people who inject drugs are engaged in needed care for chronic HCV infection; Early engagement in treatment needs to be a policy priority for these individuals.

Published
06 October 2015
From
NYU press release
ContraVir Reports New Data demonstrating CMX157 to be 60-Fold More Potent Against Hepatitis B Virus than Gilead's Viread®

The Company believes CMX157's lipid-conjugate design clearly differentiates it from tenofovir DF. ContraVir plans to file an investigational new drug (IND) application for CMX157 to treat HBV before year-end 2015. CMX157 benefits from earlier human studies in volunteers under an IND for HIV. ContraVir is focused on a quick evaluation of CMX157 in a Phase 2 clinical study in patients with hepatitis B which it plans to begin in 2016.

Published
06 October 2015
From
Contravir press release
Treating 5 percent of hepatitis C patients with new drugs would reduce cost and infections, study shows

The health care system would save more lives and money if patients were treated with the latest drugs earlier, researchers at USC and other institutions find.

Published
06 October 2015
From
USC News
New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment

A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta – EDP-239 – was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in

Published
05 October 2015
By
Liz Highleyman
FixHepC, the buyers club for hepatitis C drug, inundated with inquiries

A new Dallas-style buyers club to help thousands of hepatitis C sufferers get life-saving drugs at a fraction of the cost being charged by a pharmaceutical giant has been inundated with inquiries in its first week.

Published
02 October 2015
From
Sydney Morning Herald
Hepatitis C drug buyers club aims to set up new source of support

A group of campaigning patients and doctors has launched a Dallas Buyers' Club-style operation to help Australia's estimated 233,000 hepatitis C sufferers get new life-saving drugs without paying astronomical bills.

Published
28 September 2015
From
Sydney Morning Herald
Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes

If Approved, SOF/VEL Would be the First All-Oral Pan-Genotypic Single Tablet Regimen for Chronic HCV. U.S. NDA and European MAA Submissions Planned for Q4. 2015.

Published
21 September 2015
From
Gilead press release

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.